HR 7269 · 116th Congress 2019โ€“2021, ended

Promising Pathway Act

Latest action · Jun 18, 2020 Referred to the House Committee on Energy and Commerce.

Progress

Where this bill reached, and when. A stage with no date was not reached; one that failed a vote and later carried shows the date it carried.

  1. IntroducedJun 18, 2020
  2. Passed HouseNot reached
  3. Passed SenateNot reached
  4. To the PresidentNot reached
  5. Became lawNot reached

Summary

Promising Pathway Act

This bill establishes a provisional approval pathway for medicines intended for serious or life-threatening diseases, including illnesses posing a threat of epidemic or pandemic. The period of the provisional approval is for two years and is potentially renewable.

The Food and Drug Administration (FDA) must establish a priority review system to evaluate completed provisional approval applications within 90 days of receipt. A provisional approval application may be approved if the FDA determines that (1) there is substantial evidence of safety for the drug; and (2) there is relevant early evidence of efficacy, based on adequate and well-controlled investigations.

During the COVID-19 (i.e., coronavirus disease 2019) pandemic, or another epidemic or pandemic, the FDA must accept and review various portions of a provisional approval application on a rolling basis.

The manufacturer of a provisionally approved drug must require patients to participate in an observational registry. A manufacturer that fails to comply with registry requirements is subject to civil penalties.

A provisionally approved drug must be labeled as such.

If a drug that receives provisional approval status is not brought to market within 180 days of the approval, the approval must be rescinded.

The bill also limits the liability of a manufacturer of a provisionally approved drug with respect to any claim under state law alleging that the drug is unsafe or ineffective.

Private health insurers and federal health care programs shall not deny coverage of a provisionally approved drug on the basis of it being experimental.

Cosponsors 11

Members who signed on, in the order they did. Signatures ran from Jun 18, 2020 to Aug 21, 2020; 3 are original cosponsors, there from the day it was introduced.

SeatCosponsorSigned on
R-ARBruce WestermanOriginalJun 18, 2020
D-CAEric SwalwellOriginalJun 18, 2020
R-WIMike GallagherOriginalJun 18, 2020
D-CAGrace F. NapolitanoJul 16, 2020
D-NJJefferson Van DrewJul 16, 2020
R-NEDon BaconJul 23, 2020
R-PABrian K. FitzpatrickJul 24, 2020
D-MNAngie CraigJul 29, 2020
R-NYPeter T. KingJul 29, 2020
D-OHJoyce BeattyAug 14, 2020
R-FLTed S. YohoAug 21, 2020

Committees 1

Where it was sent and what each committee and subcommittee did with it, in order.

ChamberCommitteeWhat it did
HouseEnergy and Commerce Committee
Referred Jun 18, 2020

Actions 2

Everything that happened, newest first.

  1. Jun 18, 2020Introduced in House
  2. Jun 18, 2020Referred to the House Committee on Energy and Commerce.

Research

What has been written about this bill: committee reports, cost estimates, the sponsor’s authority statement, printed hearings and the Congressional Research Service’s work.

Constitutional authority

Congress has the power to enact this legislation pursuant to the following: Article 1, Section 8, Clause 3 of the U.S. Constitution

The sponsor’s statement, as printed in the Congressional Record, vol. 166, no. 113, June 18, 2020, page H2407.

Related bills 1

Companion bills and other measures the record links to this one.

BillTitleRelationshipLatest action
S 3872Promising Pathway ActIdentical billJun 3, 2020

Titles 2

Every title it has carried, official and short, at each stage.

Official Title as Introduced
To amend the Federal Food, Drug, and Cosmetic Act to establish a time-limited provisional approval pathway, subject to specific obligations, for certain drugs and biological products, and for other purposes.
Short Title(s) as Introduced
Promising Pathway Act

Subjects

Assigned by the Library of Congress. Policy area: Health.

Text 1

Each version as it was printed, newest first.

  1. Jun 18, 2020Introduced in House

Support LegiList

This page is free, carries no paywall, and is built and maintained by one person. If the record here is useful to you, a few dollars keeps it going.

Processed by Stripe in a separate window. LegiList never sees card details.

Everything here is as published by Congress: the summary is the Congressional Research Service's, the action wording is the clerks', and the subjects are the Library of Congress's. How far it got is read from the actions themselves, taking the most recent one of each kind, so a bill that failed a vote and later passed is shown as having passed. Records come from this bill on Congress.gov and govinfo.gov; cost estimates are the Congressional Budget Office's, and the hearings are the printed hearings GovInfo publishes, which can appear months after the hearing.